Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2004

Open Access 01-12-2004 | Review

T-cell clonotypes in cancer

Authors: Per thor Straten, David Schrama, Mads Hald Andersen, Jürgen C Becker

Published in: Journal of Translational Medicine | Issue 1/2004

Login to get access

Abstract

Cells of the immune system spontaneously recognize autologous tumor cells and T cells are believed to be the main effector cells for the immune surveillance of cancer. Recent advances in our understanding of basic and tumor immunology together with methodological developments implies that tumor specific T cells can now be studied functionally, phenotypically as well as molecularly. T cells recognize peptide antigens in the context of MHC molecules through the clonally distributed T-cell receptor (TCR), thus, the clonal distribution of the TCR offers the means to detect and track specific T cells based upon detection of the unique TCR. In this review, we present and discuss available data on TCR utilization of tumor specific T cells in murine models as well as spontaneous and treatment induced anti-tumor T-cell responses in humans.
Literature
1.
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991, 254: 1643-1647.CrossRefPubMed
2.
Renkvist N, Castelli C, Robbins PF, Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother. 2001, 50: 3-15. 10.1007/s002620000169.CrossRefPubMed
3.
Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U: Natural T cell immunity against cancer. Clin Cancer Res. 2003, 9: 4296-4303.PubMed
4.
Rammensee HG, Falk K, Roetzschke O: MHC molecules as peptide receptors. Curr Biol. 1995, 5: 35-44.CrossRef
5.
Schuler G, Schuler-Thurner B, Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003, 15: 138-147. 10.1016/S0952-7915(03)00015-3.CrossRefPubMed
6.
Schmittel A, Keilholz U, Thiel E, Scheibenbogen C: Quantification of tumor-specific T lymphocytes with the ELISPOT assay. J Immunother. 2000, 23: 289-295. 10.1097/00002371-200005000-00001.CrossRefPubMed
7.
Altman JD, Moss PA, Goulder PJR, Barouch DH, McHeyzer Williams MG, Bell JI, McMichael AJ, Davis MM: Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996, 274: 94-96. 10.1126/science.274.5284.94.CrossRefPubMed
8.
Andersen MH, Ostergaard Pedersen L, Capeller B, Bröcker EB, Becker JC, thor Straten P: Spontaneous cytoxic T-cell responses against survivin-derived MHC class I restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001, 61: 5964-5968.PubMed
9.
Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998, 4: 328-332.CrossRefPubMed
10.
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998, 4: 321-327.PubMedCentralCrossRefPubMed
11.
Parmiani G, Pilla L, Castelli C, Rivoltini L: Vaccination of patients with solid tumours. Ann Oncol. 2003, 14: 817-824. 10.1093/annonc/mdg246.CrossRefPubMed
12.
Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola FM, Worobec A, Atkins MB: Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother. 2002, 25: 97-138. 10.1097/00002371-200203000-00001.CrossRefPubMed
13.
Arden B, Clark SP, Kabelitz D, Mak TW: Human T-cell receptor variable gene segment families. Immunogenetics. 1995, 42: 455-500.PubMed
14.
15.
Nitta T, Oksenberg JR, Rao NA, Steinman RM: Predominant expression of T cell receptor V alpha 7 in tumor- infiltrating lymphocytes of uveal melanoma. Science. 1990, 249: 672-674.CrossRefPubMed
16.
Oksenberg JR, Stuart S, Begovich AB, Bell RB, Erlich HA, Steinman RM, Bernard CC: Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients [published erratum appears in Nature 1991 Sep 5;353(6339):94]. Nature. 1990, 345: 344-346. 10.1038/345344a0.CrossRefPubMed
17.
Sensi M, Parmiani G: Analysis of TCR usage in human tumors:a new tool for assessing tumor-specific immune responses. Immunol Today. 1995, 16: 588-595. 10.1016/0167-5699(95)80082-4.CrossRefPubMed
18.
Pannetier C, Even J, Kourilsky P: T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today. 1995, 16: 176-181. 10.1016/0167-5699(95)80117-0.CrossRefPubMed
19.
thor Straten P, Schøller J, Hou Jensen K, Zeuthen J: Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. Int J Cancer. 1994, 56: 78-86.CrossRefPubMed
20.
thor Straten P, Becker JC, Seremet T, Bröcker EB, Zeuthen J: Clonal T-cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human melanoma. J Clin Invest. 1996, 98: 279-284.PubMedCentralCrossRefPubMed
21.
Salvi S, Segalla F, Rao S, Arienti F, Sartori M, Bratina G, Caronni E, Anichini A, Clemente C, Parmiani G, Sensi M: Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res. 1995, 55: 3374-3379.PubMed
22.
Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P: Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol. 1994, 153: 2807-2818.PubMed
23.
Ferradini L, Roman Roman S, Azocar J, Avril MF, Viel S, Triebel F, Hercend T: Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis. Cancer Res. 1992, 52: 4649-4654.PubMed
24.
Ferradini L, Mackensen A, Genevee C, Bosq J, Duvillard P, Avril MF, Hercend T: Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest. 1993, 91: 1183-1190.PubMedCentralCrossRefPubMed
25.
Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, Hercend T: Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 1993, 53: 3569-3573.PubMed
26.
Hishii M, Andrews D, Boyle LA, Wong JT, Pandolfi F, van den Elsen PJ, Kurnick JT: In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites. Proc Natl Acad Sci USA. 1997, 94: 1378-1383. 10.1073/pnas.94.4.1378.PubMedCentralCrossRefPubMed
27.
Wack A, Montagna D, Dellabona P, Casorati G: An improved PCR-heteroduplex method permits high-sensitivity detection of clonal expansions in complex T cell populations. J Immunol Methods. 1996, 196: 181-192. 10.1016/0022-1759(96)00114-7.CrossRefPubMed
28.
Bousso P, Kourilsky P: A clonal view of alphabeta T cell responses. Semin Immunol. 1999, 11: 423-431. 10.1006/smim.1999.0200.CrossRefPubMed
29.
thor Straten P, Barfoed A, Seremet T, Säterdal I, Zeuthen J, Guldberg P: Detection and Characterization of alpha/beta-T-cell Clonality by Denaturing Gradient Gel Electrophoresis (DGGE). Biotechniques. 1998, 25: 244-250.PubMed
30.
Pannetier C, Cochet M, Darche S, Casrouge A, Zöller M, Kourilsky P: The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci USA. 1993, 90: 4319-4323.PubMedCentralCrossRefPubMed
31.
thor Straten P, Guldberg P, Grønbæk K, Zeuthen J, Becker JC: In Situ T-Cell Responses against Melanoma Comprise High Numbers of Locally Expanded T-Cell Clonotypes. J Immunol. 1999, 163: 443-447.PubMed
32.
Moerch U, Schrama D, Guldberg P, Seremet T, Zeuthen J, Becker JC, thor Straten P: Comparative delineantion of T cell clonotypes in coexisting syngeneic B16 melanoma. Cancer Immunol Immunother. 2000, 49: 426-432. 10.1007/s002620000136.CrossRefPubMed
33.
thor Straten P, Becker JC, Zeuthen J, Guldberg P: T-cell receptor clonotype mapping using denaturing gradient gel electrophoresis (DGGE): Analyses of clonal T-cell responses in melanoma. Melanoma Methods and Protocols Edited by: NicholoffB. Humana Press. Inc.; 2001.
34.
thor Straten P, Guldberg P, Hald Andersen M, Moerch U, Seremet T, Siedel C, Zeuthen J, Reisfeld RA, Becker JC: In situ cytokine therapy: Redistribution of clonally expanded therapeutic T-cell clones. Eur J Immunol. 2001, 31: 250-258. 10.1002/1521-4141(200101)31:1<250::AID-IMMU250>3.3.CO;2-#.CrossRefPubMed
35.
Pilch H, Hohn H, Freitag K, Neukirch C, Necker A, Haddad P, Tanner B, Knapstein PG, Maeurer MJ: Improved assessment of T-cell receptor (TCR) VB repertoire in clinical specimens: combination of TCR-CDR3 spectratyping with flow cytometry-based TCR VB frequency analysis. Clin Diagn Lab Immunol. 2002, 9: 257-266. 10.1128/CDLI.9.2.257-266.2002.PubMedCentralPubMed
36.
Andersen MH, Gehl J, Reker S, Ostergaard Pedersen L, Becker JC, Geertsen PF, thor Straten P: Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol. 2003, 13: 449-459. 10.1016/j.semcancer.2003.09.009.CrossRefPubMed
37.
Lim A, Baron V, Ferradini L, Bonneville M, Kourilsky P, Pannetier C: Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8+ T cell immune responses. J Immunol Methods. 2002, 261: 177-194. 10.1016/S0022-1759(02)00004-2.CrossRefPubMed
38.
Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A: Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J Natl Cancer Inst. 2002, 94: 805-818. 10.1093/jnci/94.11.805.CrossRefPubMed
39.
Schrama D, Andersen MH, Terheyden P, Schrøder L, Ostergaard Pedersen L, thor Straten P, Becker JC: Oligoclonal TCR usage of melanocyte differentiation antigen-reactive T cells. Cancer Res. 2001, 61: 493-496.PubMed
40.
Dietrich PY, Walker PR, Quiquerez AL, Perrin G, Dutoit V, Lienard D, Guillaume P, Cerottini JC, Romero P, Valmori D: Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res. 2001, 61: 2047-2054.PubMed
41.
Bilsborough J, Van Pel A, Uyttenhove C, Boon T, Van den Eynde BJ: Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. J Immunol. 1999, 162: 3534-3540.PubMed
42.
Lethe B, van den Eynde B., Van Pel A, Corradin G, Boon T: Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol. 1992, 22: 2283-2288.CrossRefPubMed
43.
Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP: gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"- reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998, 188: 277-286. 10.1084/jem.188.2.277.PubMedCentralCrossRefPubMed
44.
Siegel S, Wagner A, Schmitz N, Zeis M: Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol. 2003, 122: 911-914. 10.1046/j.1365-2141.2003.04535.x.CrossRefPubMed
45.
Bloom MB, Perry-Lalley D, Robbins PF, Li Y, El-Gamil M, Rosenberg SA, Yang JC: Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997, 185: 453-459. 10.1084/jem.185.3.453.PubMedCentralCrossRefPubMed
46.
Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L., Fleuren GJ, Kenemans P, Kast WM, Melief CJ: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med. 1997, 186: 695-704. 10.1084/jem.186.5.695.PubMedCentralCrossRefPubMed
47.
Mumberg D, Wick M, Schreiber H: Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol. 1996, 8: 289-293. 10.1006/smim.1996.0037.CrossRefPubMed
48.
Levraud JP, Pannetier C, Langlade-Demoyen P, Brichard V, Kourilsky P: Recurrent T cell receptor rearrangenments in the cytotoxic T lymphocyte response In Vivo against P815 murine tumor. J Exp Med. 1996, 183: 439-449.CrossRefPubMed
49.
Cibotti R, Cabaniols JP, Pannetier C, Delarbre C, Vergnon I, Kanellopoulos JM, Kourilsky P: Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice. J Exp Med. 1994, 180: 861-872.CrossRefPubMed
50.
thor Straten P, Guldberg P, Seremet T, Reisfeld RA, Zeuthen J, Becker JC: Activation of pre-existing T-cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci USA. 1998, 95: 8785-8790. 10.1073/pnas.95.15.8785.PubMedCentralCrossRef
51.
Schrama D, thor Straten P, Fischer WH, Merkel A, Bröcker EB, Reisfeld RA, Becker JC: Targeting lymphotoxin alpha to the tumor microenvironment elicits an efficient immune response by induction of peripheral lymphoid tissue. Immunity. 2001, 14: 111-121.CrossRefPubMed
52.
Andersen MH, Reker S, Becker JC, thor Straten P: The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol. 2004, 122: 392-399. 10.1111/j.0022-202X.2004.22508.x.CrossRefPubMed
53.
Sensi M, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, Nicolini G, Herlyn M, Parmiani G, Anichini A: T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med. 1993, 178: 1231-1246.CrossRefPubMed
54.
Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994, 91: 3515-3519.PubMedCentralCrossRefPubMed
55.
Coulie PG, Brichard V, Van Pel A, Wölfel T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, et al: A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994, 180: 35-42.CrossRefPubMed
56.
Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wölfel T, et al: Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2- restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA. 1995, 92: 5674-5678.PubMedCentralCrossRefPubMed
57.
Mackensen A, Carcelain G, Viel S, Raynal MC, Michalaki H, Triebel F, Bosq J, Hercend T: Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest. 1994, 93: 1397-1402.PubMedCentralCrossRefPubMed
58.
Pisarra P, Mortarini R, Salvi S, Anichini A, Parmiani G, Sensi M: High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition. Cancer Immunol Immunother. 1999, 48: 39-46. 10.1007/s002620050546.CrossRefPubMed
59.
Valmori D, Dutoit V, Lienard D, Lejeune F, Speiser D, Rimoldi D, Cerundolo V, Dietrich PY, Cerottini JC, Romero P: Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J Immunol. 2000, 165: 533-538.CrossRefPubMed
60.
Dietrich PY, Walker PR, Quiquerez AL, Perrin G, Dutoit V, Lienard D, Guillaume P, Cerottini JC, Romero P, Valmori D: Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. Cancer Res. 2001, 61: 2047-2054.PubMed
61.
Romero P, Pannetier C, Herman J, Jongeneel CV, Cerottini JC, Coulie PG: Multiple specificities in the repertoire of a melanoma patients cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J Exp Med. 1995, 182: 1019-1028.CrossRefPubMed
62.
Lehner PJ, Wang EC, Moss PA, Williams S, Platt K, Friedman SM, Bell JI, Borysiewicz LK: Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. J Exp Med. 1995, 181: 79-91.CrossRefPubMed
63.
Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S, Wang C, Davis MM: Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest. 2003, 111: 639-647. 10.1172/JCI200316398.PubMedCentralCrossRefPubMed
64.
Becker JC, Guldberg P, Zeuthen J, Bröcker EB, thor Straten P: Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol. 1999, 113: 1033-1038. 10.1046/j.1523-1747.1999.00805.x.CrossRefPubMed
65.
Ogg GS, Rod Dunbar P., Romero P, Chen JL, Cerundolo V: High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med. 1998, 188: 1203-1208. 10.1084/jem.188.6.1203.PubMedCentralCrossRefPubMed
66.
Mantovani S, Garbelli S, Palermo B, Campanelli R, Brazzelli V, Borroni G, Martinetti M, Benvenuto F, Merlini G, della Cuna GR, Rivoltini L, Giachino C: Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. J Invest Dermatol. 2003, 121: 308-314. 10.1046/j.1523-1747.2003.12368.x.CrossRefPubMed
67.
Schrama D, Eggert AA, Brocker EB, Pedersen LO, thor Straten P, Becker JC: Immunological consequences of the sentinel lymph-node biopsy--lessons from a melanoma patient. Lancet Oncol. 2003, 4: 446-447. 10.1016/S1470-2045(03)01143-4.CrossRefPubMed
68.
69.
Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, Klein HG, Marincola FM: Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 2002, 3: RESEARCH0035-10.1186/gb-2002-3-7-research0035.PubMedCentralCrossRefPubMed
70.
Willhauck M, Scheibenbogen C, Pawlita M, Mohler T, Thiel E, Keilholz U: Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy. Cancer Res. 2003, 63: 3483-3485.PubMed
71.
Schrama D, Fuchs E, Brocker EB, thor Straten P, Becker JC: Identical T-cell receptor transcripts in multiple melanoma metastases. Cancer Res. 2002, 62: 5664-5667.PubMed
72.
Sensi M, Farina C, Maccalli C, Lupetti R, Nicolini G, Anichini A, Parmiani G, Berd D: Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J Clin Invest. 1997, 99: 710-717.PubMedCentralCrossRefPubMed
73.
Sensi M, Farina C, Maccalli C, Anichini A, Berd D, Parmiani G: Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination. J Immunother. 1998, 21: 198-204.CrossRefPubMed
74.
Manne J, Mastrangelo MJ, Sato T, Berd D: TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine. J Immunol. 2002, 169: 3407-3412.CrossRefPubMed
75.
Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Naeyaert JM, Plangne R, Deraemaeker R, Knuth A, Jäger E, Brasseur F, Herman J, Coulie PG, Boon T: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer. 1995, 63: 883-885.CrossRefPubMed
76.
Valmori D, Dutoit V, Schnuriger V, Quiquerez AL, Pittet MJ, Guillaume P, Rubio-Godoy V, Walker PR, Rimoldi D, Lienard D, Cerottini JC, Romero P, Dietrich PY: Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol. 2002, 168: 4231-4240.CrossRefPubMed
77.
thor Straten P, Kirkin AF, Siim E, Dahlstrom K, Drzewiecki KT, Seremet T, Zeuthen J, Becker JC, Guldberg P: Tumor infiltrating lymphocytes (TIL) in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture. Clin Immunol. 2000, 96: 94-99. 10.1006/clim.2000.4890.CrossRefPubMed
78.
Faure F, Even J, Kourilsky P: Tumor-specific immune response: current in vitro analyses may not reflect the in vivo immune status. Crit Rev Immunol. 1998, 18: 77-86.CrossRefPubMed
79.
Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA: Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am. 1998, 4: 316-323.PubMed
80.
Terheyden P, Schrama D, Pedersen LO, Andersen MH, Kampgen E, thor Straten P, Becker JC: Longitudinal analysis of MART-1/HLA-A2-reactive T cells over the course of melanoma progression. Scand J Immunol. 2003, 58: 566-571. 10.1046/j.1365-3083.2003.01324.x.CrossRefPubMed
81.
Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, van Baren N, Boon T: Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev. 2002, 188:33-42.: 33-42. 10.1034/j.1600-065X.2002.18804.x.CrossRef
82.
Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T: A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA. 2001, 98: 10290-10295. 10.1073/pnas.161260098.PubMedCentralCrossRefPubMed
83.
Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A: Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol. 2003, 171: 4893-4897.CrossRefPubMed
84.
Schrama D, Ostergaard Pedersen L, Keikavoussi P, Andersen MH, thor Straten P, Brocker EB, Kampgen E, Becker JC: Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells. J Invest Dermatol. 2002, 119: 1443-1448. 10.1046/j.1523-1747.2002.19604.x.CrossRefPubMed
85.
Berger TG, Haendle I, Schrama D, Lüftl M, Bauer N, Ostergaard Pedersen L, Schuler-Thurner B, Hohenberger W, thor Straten P, Schuler G, Becker JC: Circulation and homing of melanoma-reactive T cell clones to both cutaneaus and visceral metastases. Int J Cancer. 2004, In Press.:
86.
Rosenberg SA, Spiess PJ, Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor- infiltrating lymphocytes. Science. 1986, 233: 1318-1321.CrossRefPubMed
87.
Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumor- infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994, 86: 1159-1166. 10.1093/jnci/86.15.1159.CrossRefPubMed
88.
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002, 298: 850-854. 10.1126/science.1076514.PubMedCentralCrossRefPubMed
89.
Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA: A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002, 25: 243-251. 10.1097/00002371-200205000-00007.PubMedCentralCrossRefPubMed
90.
Kwok WW: Challenges in staining T cells using HLA class II tetramers. Clin Immunol. 2003, 106: 23-28. 10.1016/S1521-6616(02)00018-9.CrossRefPubMed
91.
Moss PA, Moots RJ, Rosenberg WM, Rowland-Jones SJ, Bodmer HC, McMichael AJ, Bell JI: Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. Proc Natl Acad Sci U S A. 1991, 88: 8987-8990.PubMedCentralCrossRefPubMed
92.
Trautmann L, Labarriere N, Jotereau F, Karanikas V, Gervois N, Connerotte T, Coulie PG, Bonneville M: Dominant TCR V alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol. 2002, 32: 3181-3190. 10.1002/1521-4141(200211)32:11<3181::AID-IMMU3181>3.0.CO;2-2.CrossRefPubMed
93.
Dietrich PY, Le Gal FA, Dutoit V, Pittet MJ, Trautman L, Zippelius A, Cognet I, Widmer V, Walker PR, Michielin O, Guillaume P, Connerotte T, Jotereau F, Coulie PG, Romero P, Cerottini JC, Bonneville M, Valmori D: Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol. 2003, 170: 5103-5109.CrossRefPubMed
94.
Mantovani S, Palermo B, Garbelli S, Campanelli R, Robustelli della Cuna G., Gennari R, Benvenuto F, Lantelme E, Giachino C: Dominant TCR-alpha requirements for a self antigen recognition in humans. J Immunol. 2002, 169: 6253-6260.CrossRefPubMed
95.
Bankovich AJ, Garcia KC: Not just any T cell receptor will do. Immunity. 2003, 18: 7-11. 10.1016/S1074-7613(02)00517-4.CrossRefPubMed
96.
Argaet VP, Schmidt CW, Burrows SR, Silins SL, Kurilla MG, Doolan DL, Suhrbier A, Moss DJ, Kieff E, Suclley TB: Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med. 1994, 180: 2335-2340.CrossRefPubMed
97.
Kjer-Nielsen L, Clements CS, Purcell AW, Brooks AG, Whisstock JC, Burrows SR, McCluskey J, Rossjohn J: A structural basis for the selection of dominant alphabeta T cell receptors in antiviral immunity. Immunity. 2003, 18: 53-64. 10.1016/S1074-7613(02)00513-7.CrossRefPubMed
Metadata
Title
T-cell clonotypes in cancer
Authors
Per thor Straten
David Schrama
Mads Hald Andersen
Jürgen C Becker
Publication date
01-12-2004
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2004
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-2-11

Other articles of this Issue 1/2004

Journal of Translational Medicine 1/2004 Go to the issue

Research

Ambiguous allele combinations in HLA Class I and Class II sequence-based typing: when precise nucleotide sequencing leads to imprecise allele identification

Research

The role of d-dimer as first marker of thrombophilia in women affected by sterility: implications in pathophysiology and diagnosis of thrombophilia induced sterility

Review

From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference

Research

A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay

Commentary

Conflicts of interest in translational research

Commentary

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits